BioMarin Pharmaceutical(US:BMRN)2025-10-27 20:30Financial Performance - Year-to-date 2025 total revenues increased by 11% year-over-year, driven by over 20% year-over-year revenue growth for PALYNZIQ and VOXZOGO[11] - The company raised full-year 2025 total revenues guidance to between $3150 million and $3200 million, representing 11% fiscal year 2025 growth year-over-year[13] - VOXZOGO's fiscal year 2025 revenue outlook is reaffirmed to be between $900 million and $935 million[13] - Q3 2025 GAAP operating margin was negative 60%, a decrease of 213 percentage points year-over-year, while non-GAAP operating margin was 28%, a decrease of 249 percentage points year-over-year[21] - Q3 2025 GAAP diluted EPS was negative $016, a decrease of 129%, while non-GAAP diluted EPS was $012, a decrease of 87%[21] - Operating cash flow for Q3 2025 was $369 million, an increase of 66%[21] - Full-year 2025 non-GAAP operating margin guidance updated to 26% - 27% and non-GAAP diluted EPS guidance updated to $350 - $360[24] Product Performance - VOXZOGO Q3 year-to-date revenue increased 24% year-over-year[20] - Enzyme Therapies Q3 year-to-date revenue increased 8% year-over-year[20] - VOXZOGO Q3 2025 revenue was $218 million, a 15% increase year-over-year, and Q3 2025 year-to-date revenue was $654 million, a 24% increase year-over-year[33] Research and Development - The company is preparing for VOXZOGO in hypochondroplasia (HCH) launch, with pivotal data readout expected in the first half of 2026[38]